Company Filing History:
22 out of 192 
1 out of 7 Years Active: 2003-2025
Title: The Innovative Contributions of Shiv Srivastava in Prostate Cancer Research
Introduction
Shiv Srivastava, based in Potomac, MD, is a prominent inventor known for his impactful contributions to the field of prostate cancer research. With a remarkable portfolio consisting of 22 patents, he has dedicated his career to developing diagnostic and treatment methods that help in better understanding and managing prostate cancer.
Latest Patents
Among his latest innovations are two noteworthy patents focused on markers for the diagnosis of biochemical recurrence (BCR) in prostate cancer. His methods involve detecting levels of various biomarkers indicative of BCR, facilitating early detection and timely intervention. Additionally, he has developed prostate cancer gene profiles that differentiate between subjects of African and Caucasian descent. These gene expression profiles assist in stratifying prostate cancer based on ethnicity and can be measured at both the nucleic acid and protein levels. His work also includes the creation of kits for diagnosing and prognosing prostate cancer, which are vital tools for healthcare providers.
Career Highlights
Shiv has had a distinguished career, having contributed significantly while working at esteemed organizations, such as the Henry M. Jackson Foundation for the Advancement of Military Medicine and Bpgbio, Inc. His work has not only advanced scientific knowledge but also practical applications that enhance patient care in oncology.
Collaborations
Throughout his career, Shiv has collaborated with notable individuals in the field, including Gyorgy Petrovics and Albert Dobi. These partnerships have fostered a collaborative environment conducive to innovation and development in cancer research.
Conclusion
Shiv Srivastava's contributions to prostate cancer research through his patents reflect a dedication to improving diagnostic methods and treatment options. His work continues to pave the way for advancements in the understanding and management of prostate cancer, making a significant impact on patient outcomes and healthcare practices.